AstraZeneca has completed an agreement with Atnahs Pharma, a UK-based pharmaceutical company, to divest its global commercial rights for five established hypertension medicines for $350 million.

The medicines include Inderal (propranolol), a beta blocker for treating tremors, angina, hypertension, arrhythmias, and other heart or circulatory conditions; Tenormin (atenolol), a beta blocker for treating angina and hypertension, as well as certain kinds of arrhythmia;  Tenoretic (atenolol, chlorthalidone fixed-dose combination), a beta blocker and diuretic for treating high blood pressure; Zestril (lisinopril), an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease hypertension; and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination), an ACE inhibitor and diuretic for hypertension.

Under the agreement, AstraZeneca has received a payment of $350 million from Atnahs. The company may also receive future sales-contingent payments of up to $40 million between 2020 and 2022.

Source: AstraZeneca